Bio Trion

BioTrion is a biotechnology company focused on developing next-generation multi-specific antibody therapeutics for cancer immunotherapy. The company utilizes its proprietary TriTE (Tri-specific T-cell Engager) platform to engineer antibodies capable of simultaneously targeting T-cells and multiple tumor antigens. This approach is designed to enhance the recruitment and activation of the immune system while reducing the likelihood of tumor escape through antigen loss. BioTrion's pipeline includes candidates for both hematological malignancies and solid tumors, positioning the company at the forefront of advanced biologics engineering. By targeting two different tumor-associated antigens alongside CD3, their molecules aim to provide superior efficacy and safety compared to traditional bispecific T-cell engagers.